Challenge:

A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over the counter medicines wanted to supplement their internal pipeline with novel parenterally delivered small molecules, peptides, or nucleic acid assets at advanced stages of clinical development. Alacrita was asked to identify innovations in formulations and/or devices in development for Oncology, Immunology, Autoimmune, or Endocrine indications.

Solution:

Alacrita proposed a 3-month scouting engagement and, due to the target stage of development of interest, we utilized a commercial pipeline database search. Our initial search identified over 5,000 potential candidate assets. To facilitate the asset search process, Alacrita developed a prioritization score derived from several asset specific parameters, including asset modality, disease segment, formulation approach and level of innovation, drug delivery method, platform technology potential, and asset owner company profile. Each of these parameters were scored individually and used to derive the final prioritization score for ranking assets. We ultimately identified 65 prioritized assets that were a strong fit for the client’s search criteria. We contacted all 65 companies and requested non-confidential (NC) slide decks. We received NC slide decks from 17 companies, which led to further partnering discussions.

Explore Our Asset Scouting & In-Licensing Services

Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our asset scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.